Cargando…

Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients

The most commonly used antiviral treatment against hepatitis C virus is a combination of direct-acting antivirals (DAAs) and ribavirin (RBV), which leads to a shortened duration of therapy and a sustained virologic response until 98%. Nonetheless, several dose-related side effects of RBV could limit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giampaoli, Ottavia, Sciubba, Fabio, Biliotti, Elisa, Spagnoli, Mariangela, Calvani, Riccardo, Tomassini, Alberta, Capuani, Giorgio, Miccheli, Alfredo, Taliani, Gloria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456413/ https://www.ncbi.nlm.nih.gov/pubmed/36077436 http://dx.doi.org/10.3390/ijms231710043

Ejemplares similares

Metabolic Biomarkers of Red Beetroot Juice Intake at Rest and after Physical Exercise
por: Giampaoli, Ottavia, et al.
Publicado: (2023)

Red Beetroot’s NMR-Based Metabolomics: Phytochemical Profile Related to Development Time and Production Year
por: Giampaoli, Ottavia, et al.
Publicado: (2021)

Can the FUT2 Non-secretor Phenotype Associated With Gut Microbiota Increase the Children Susceptibility for Type 1 Diabetes? A Mini Review
por: Giampaoli, Ottavia, et al.
Publicado: (2020)

Hyperbaric Exposure of Scuba Divers Affects the Urinary Excretion of Nucleic Acid Oxidation Products and Hypoxanthine
por: Marchetti, Enrico, et al.
Publicado: (2022)

Biomonitoring of Exposure to Urban Pollutants and Oxidative Stress during the COVID-19 Lockdown in Rome Residents
por: Buonaurio, Flavia, et al.
Publicado: (2022)

Longitudinal Multi-Omics Study of a Mother-Infant Dyad from Breastfeeding to Weaning: An Individualized Approach to Understand the Interactions Among Diet, Fecal Metabolome and Microbiota Composition
por: Conta, Giorgia, et al.
Publicado: (2021)

Biostimulant Effects of Chaetomium globosum and Minimedusa polyspora Culture Filtrates on Cichorium intybus Plant: Growth Performance and Metabolomic Traits
por: Spinelli, Veronica, et al.
Publicado: (2022)

820 Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b
por: Brunetto, Maurizia, et al.
Publicado: (2014)

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
por: Botticelli, Andrea, et al.
Publicado: (2020)

2-hydroxyisobutyric acid (2-HIBA) modulates ageing and fat deposition in Caenorhabditis elegans
por: Schifano, Emily, et al.
Publicado: (2022)

Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients
por: Vernocchi, Pamela, et al.
Publicado: (2020)

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study
por: Spaziante, Martina, et al.
Publicado: (2021)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Leuconostoc mesenteroides Strains Isolated from Carrots Show Probiotic Features
por: Schifano, Emily, et al.
Publicado: (2021)

Short-chain fatty acids promote the effect of environmental signals on the gut microbiome and metabolome in mice
por: Marrocco, Francesco, et al.
Publicado: (2022)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Farcomeni, Stefania, et al.
Publicado: (2021)

In Vitro Probiotic Properties and In Vivo Anti-Ageing Effects of Lactoplantibacillus plantarum PFA2018AU Strain Isolated from Carrots on Caenorhabditis elegans
por: Pompa, Laura, et al.
Publicado: (2023)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
por: Taramasso, Lucia, et al.
Publicado: (2018)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV
por: Smith, Anton A. A., et al.
Publicado: (2015)

HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives
por: Maffei, Laura, et al.
Publicado: (2020)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
por: Leung, Daniel H., et al.
Publicado: (2018)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders
por: Fuchs, Michael, et al.
Publicado: (2020)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report
por: Spaziante, Martina, et al.
Publicado: (2019)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection
por: Pogorzelska, Joanna, et al.
Publicado: (2016)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_81u9f4ducd1hece4j14i8ljloc